Kymera reports positive KT-621 phase 1 Japanese study results
Kymera Therapeutics (NASDAQ:KYMR) reported positive findings from its Phase 1 clinical trial evaluating KT-621, a first-in-class oral small…
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with…